In a phase I/II trial at MD Anderson Cancer Center, 68% of patients with B-cell lymphoma survived for at least one year after receiving NK cells from umbilical-cord blood, indicating comparable efficacy to T-cell therapies with fewer side effects.
NK cells have a better safety record than T cells, allowing for potentially more cost-effective and efficient off-the-shelf therapies, where cells from an unrelated donor are frozen and ready for use in any patient.
Collection
[
|
...
]